Switch to:
More From Other Websites
Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews Aug 27 2015
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review Aug 26 2015
Sarepta Upgraded On Promising Muscular-Dystrophy Drug Aug 26 2015
Sarepta gains after-hours as FDA accepts application for Duchenne drug approval Aug 25 2015
FDA Grants Priority Review to Sarepta Drug Aug 25 2015
Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne... Aug 25 2015
Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne... Aug 25 2015
Piper Jaffray Goes Overweight Sarepta, Expects FDA To Accept Next Key Drug Filing Aug 24 2015
Sarepta Therapeutics upgraded by Piper Jaffray Aug 24 2015
Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the... Aug 21 2015
Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the... Aug 21 2015
The FDA Is Basically Approving Everything. Here's The Data To Prove It Aug 20 2015
Treating Female Sexual Dysfunction (And How To Invest In It) Aug 19 2015
Sarepta Therapeutics Made Investors Millionaires in 2 Years Aug 14 2015
Checkmate Pharma is latest cancer drug firm focused on immune system (BBJ photo gallery) Aug 12 2015
Sarepta Therapeutics Announces Formation of Strategic & Scientific Advisory Board Aug 12 2015
Sarepta Therapeutics Announces Formation of Strategic & Scientific Advisory Board Aug 12 2015
This Undervalued Biotech Company Just Filed For FDA Approval and No One Noticed Aug 11 2015


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK